Gilead Sciences, Inc. (GILD) Balance Sheet

The reported equity collapse from $23.5B to $11.7B in a single quarter, alongside a $10.4B operating loss, suggests a substantial non-cash impairment that has artificially improved leverage ratios. Excluding this distortion, the underlying balance sheet appears stable, with total assets fluctuating around $55-59B over the past year. Investors should monitor whether this deleveraging reflects a strategic shift or merely accounting noise, as the core HIV franchise continues to generate steady cash flows.

The D/E ratio dropped from 0.95 to 0.21, but this is largely a function of the equity base shrinking, not a genuine reduction in leverage. If the debt was indeed retired, it would imply a massive cash outflow not visible in the cash flow statement, which showed only $109M in acquisitions. More plausibly, the debt may have been converted to equity or written off as part of the impairment, warranting a closer look at the footnotes. Regardless, the company's interest coverage appears comfortable given its strong operating cash flow, but the sudden change raises questions about the quality of the balance sheet.

The stability of goodwill suggests no additional impairments beyond the Q2 charge, but the concentration in intangibles exposes Gilead to future write-downs if oncology assets underperform. The modest PPE increase reflects investments in cell therapy manufacturing, yet the overall asset base remains asset-light, consistent with a specialty pharma model. The $10.4B impairment in Q2 likely hit other intangibles, not goodwill, which may indicate that the company is cleaning up past acquisition overpayments.

This dramatic reduction in equity quality suggests that past acquisitions have not generated the expected returns, forcing a massive write-down. While the company continues to pay dividends and buy back shares, the equity base is now thinner, potentially limiting financial flexibility. The positive retained earnings balance indicates that Gilead has not yet eroded its entire cushion, but the trend is concerning if further impairments occur.

The decline in cash and current ratio may reflect debt repayment or funding the impairment, but the company still maintains a positive working capital position. With quarterly operating cash flow around $3.6B, Gilead can cover its near-term obligations, but the reduced cash buffer leaves less room for unexpected shocks. The low debt level provides additional comfort, though the sudden changes warrant monitoring.